Table 1 Baseline characteristics of patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer recruited to study and assessed t hroughout chemotherapy
Advanced NSCLC | Metastatic melanoma | Metastatic breast cancer | ||||
|---|---|---|---|---|---|---|
Recruited 28 men, 15 women | Assessed 15 men, four women | Recruited 13 men, seven women | Assessed nine men, three women | Recruited 20 women | Assessed 10 women | |
Age (years) | 59.5 (8.5)a | 59.0 (7.1) | 55.9 (9.2) | 54.4 (7.1) | 52.4 (9.7) | 55.9 (6.5)a |
Weight change over the previous 4 months (%) | −7 (−27–16)b | −7 (−18–7) | −2.9 (−1–6.0) | −2.5 (−13–11) | 8.5 (−27–27) | 3 (−15–12) |
BMI (kg m−2) | 24.1 (4.3) | 24.7 (4.5) | 25.6 (3.0) | 26.5 (2.7) | 28.4 (8.5) | 29.1 (7.2) |
Smoker | 38% | 36% | 25% | 50% | 20% | 0% |
Presence of APPR (%)c | 82% | 56% | 37% | 18% | 44% | 40% |
Karnofsky score | 78 (11) | 84 (10) | 86 (11) | 88 (12) | 87.3 (12.4) | 88 (12.5) |
Medications (n) | ||||||
Ibuprofen | 5 | 2 | 2 | 2 | 2 | 0 |
Megace | 3 | 2 | 0 | 0 | 0 | 2 |
Steroids | ||||||
Predose with chemotherapyd | 36 | 17 | 0 | 0 | 19 | 10 |
Daily prednisolone | 15 | 4 | 2 | 0 | 1 | 0 |
Response to chemotherapy | ||||||
Objective response | 22% | 37% | 20% | 17% | 38% | 10% |
Stable disease | 13% | 16% | 20% | 33% | 31% | 40% |
Progressive disease | 65% | 47% | 60% | 50% | 31% | 50% |
